Jazz Pharmaceuticals PTSD treatment fails to meet endpoints in phase 2 trial

Key takeaways:

• JZP150 is a small-molecule selective fatty acid amide hydrolase inhibitor.
• The drug did not produce a statistically significant decrease in PTSD symptom severity after 12 weeks.

Jazz Pharmaceuticals’ experimental PTSD treatment failed to meet the primary endpoint in a phase 2 trial, the company announced in a press release.

JZP150 is a small-molecule selective fatty acid amide hydrolase inhibitor, which was being evaluated for safety and efficacy in adults with PTSD. The multicenter, double-blind placebo-controlled, randomized trial tested two doses of JZP150: 4 mg and 0.3 mg.

At the end of a 12-week period, neither dose produced a statistically significant decrease from baseline in PTSD symptom severity, as measured by the Clinician Administered PTSD Scale.

The trial also did not meet secondary endpoints, which included changes in the Clinical Global Impression of Severity and Patient Global Impression of Severity scales after 12 weeks.

“We are deeply grateful to all those who supported and made this trial possible, including the patients who were enrolled, their families, our investigators and trial staff,” Rob Iannone, MD, MSCE, executive vice president and global head of research and development at Jazz Pharmaceuticals, said in the release. “We plan to fully evaluate these data; however, based on topline results we do not anticipate moving forward with additional JZP150 development in PTSD. We recognize the significant unmet need for PTSD patients and plan to share the findings from this trial with the medical community at a future date.”